Effect of acotiamide therapy and effect of combination therapy consisting of acotiamide and famotidine for patients with upper abdominal discomfort.

Effect of acotiamide therapy and effect of combination therapy consisting of acotiamide and famotidine for patients with upper abdominal discomfort. - Efficacy of acotiamide and famotidine for patients with upper abdominal discomfort.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012082

Enrollment

Registered

2013-10-28

Start date

2013-10-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Functional dyspepsia

Interventions

Famotidine Placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. The patients who request medications for chronic upper abdominal discomforts. 2. The patients that any organic diseases were not detected by gastrointestinal endoscope within 6 months.

Exclusion criteria

Exclusion criteria: 1. The patients whose chief complaints are Heartburn and/or regurgitation. 2. The patients who received eradication therapy against Helicobacter pylori within one year, and who succeeded to eliminate Helicobacter pylori. 3. The patients who took anti-acid secretory drugs and/or acotiamide. 4. THe patients who have severe comorbidity.

Design outcomes

Primary

Measure	Time frame
Comparison of the degree of symptom improvement before and after each treatment, and comparison of the degree of symptom improvement between single therapy and combination therapy	—

Secondary

Measure	Time frame
Comparison of QOL before and after treatment	—

Countries

Japan

Contacts

Public ContactMariko Hojo

Juntendo University School of Medicine Department of Gastroenterology

mhojo@juntendo.ac.jp03-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026